Dianthus Therapeutics (DNTH) Payables: 2017-2025
Historic Payables for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $6.7 million.
- Dianthus Therapeutics' Payables fell 11.45% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 51.36%. This contributed to the annual value of $4.6 million for FY2024, which is 75.44% up from last year.
- As of Q3 2025, Dianthus Therapeutics' Payables stood at $6.7 million, which was up 24.07% from $5.4 million recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' Payables peaked at $8.3 million during Q1 2025, and registered a low of $813,000 during Q2 2023.
- Its 3-year average for Payables is $4.1 million, with a median of $3.7 million in 2024.
- As far as peak fluctuations go, Dianthus Therapeutics' Payables tumbled by 75.66% in 2023, and later spiked by 453.10% in 2024.
- Quarterly analysis of 4 years shows Dianthus Therapeutics' Payables stood at $1.2 million in 2022, then surged by 123.65% to $2.6 million in 2023, then skyrocketed by 75.44% to $4.6 million in 2024, then dropped by 11.45% to $6.7 million in 2025.
- Its Payables stands at $6.7 million for Q3 2025, versus $5.4 million for Q2 2025 and $8.3 million for Q1 2025.